KYTX
Kyverna·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Strong Buy"
MACD Golden Cross
Ample Liquidity
EPS Beats Expectation
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KYTX
Kyverna Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing solutions for autoimmune diseases
5980 Horton St., STE 550, Emeryville, CA 94608
--
Kyverna Therapeutics, Inc., was incorporated in Delaware in June 2018 under the name BAIT Therapeutics, Inc., and changed its name to Kyverna Therapeutics, Inc., in October 2019. The company is a patient-centric clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The company's goal is to bring disease-modifying therapeutic benefits to patients with autoimmune diseases through a patient-centered approach, a broad platform, insights into the treatment of immune diseases, and lessons learned from the successful application of cell therapy in the medical field.
Company Financials
EPS
KYTX has released its 2025 Q3 earnings. EPS was reported at -0.85, versus the expected -0.95, beating expectations. The chart below visualizes how KYTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
